New Research by Applied Data Research Analyzes the Therapeutic and Economic Impact of generic drugs in alternative drug delivery systems
(Nashua, NH) – The anticipated stress on healthcare systems created by increasing life expectancy and the impact of conditions with socio-economic and environmental underpinnings is encouraging health sector companies to re-examine older drugs that may have efficacy and safety for treating many of the illnesses associated with aging and urban society. A number of generic drugs are being resurrected and developed with the aim of addressing indications for which newer, more powerful drugs are economically and/or physiologically unattractive. These ailments include several chronic conditions and the quality-of-life issues associated with them.
The economics of using generics for long-term drug therapy are compelling. Drugs that fall into this category include small-molecule API’s with molecular weights typically below 1000. By developing generics in new formulations that increase patient safety and compliance, market participants are focusing on product strategies that address the safety concerns of prescribers and the cost concerns of managed care decision makers. The key to interest in these older drugs often lies in the ability to employ alternative drug delivery methods, such as inhalation or transdermal technology, to bypass the upper digestive system and improve the effectiveness of the drug for a given indication.
Companies active in this segment are typically smaller with modest financial backing, hoping to capitalize on the evolving demographic factors that are expected to drive dramatic increases in treatment areas such as metabolic diseases, cognitive impairment and pain management. Because of their limited resources, these players must rely heavily on outsourcing and supply chain relationships to move their therapeutic products through the development, clinical trial and launch process. The impact of these products is already being felt in selected areas. By 2011, re-formulated generics will be a major force in a number of therapeutic segments.
More information is also available at www.applieddata.org .
About Applied Data
Applied Data Research is a healthcare therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.
Contact:
Greg Stone
Voice: 603-595-6225
www.applieddata.org
Source: Applied Data Research
Comment and add to the story without registration, but keep the comments meaningful please. Links are not accepted.
